A phase II trial of tamoxifen, premarin, methotrexate and 5-fluorouracil in metastatic breast cancer

Joseph C. Allegra, Thomas M. Woodcock, Stephen P. Richman, Kirby I. Bland, James L. Wittliff

Research output: Contribution to journalArticle

29 Scopus citations

Abstract

Complete remissions in patients with metastatic breast cancer using endocrine therapy or chemotherapy are infrequent. Breast tumors are known to be heterogeneous with respect to estrogen receptor status, and the low complete remission rate may be related to this biochemical heterogeneity. Based on laboratory experiments using human breast cancer cells in tissue culture, a phase II protocol was designed using tamoxifen, premarin, methotrexate, and 5-fluorouracil. Thus far, twenty-nine (29) patients have been entered into this study and twenty-five (25) are currently evaluable for response. Overall response rate was 72%, and 14 of 25 (56%) attained a complete remission. Toxicity was minimal. Median nadir white blood cell count was 5,800 and median nadir platelet count was 252,000. In summary, this combination chemo-hormonal therapy regimen is effective with a more than 50% complete remission rate and minimal toxicity.

Original languageEnglish (US)
Pages (from-to)93-99
Number of pages7
JournalBreast cancer research and treatment
Volume2
Issue number1
DOIs
StatePublished - Mar 1 1982
Externally publishedYes

Keywords

  • breast cancer
  • chemotherapy
  • combination chemo-hormonal therapy
  • endocrine therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'A phase II trial of tamoxifen, premarin, methotrexate and 5-fluorouracil in metastatic breast cancer'. Together they form a unique fingerprint.

  • Cite this